Source: http://www.google.com/patents/US20020026092?dq=6679960
Timestamp: 2016-09-25 20:59:39
Document Index: 494847256

Matched Legal Cases: ['art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12']

Patent US20020026092 - Ventricular restoration patch - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA ventricular patch to restore the ventricular architecture of the heart includes a sheet of biocompatible material having a generally oval configuration, and a continuous ring fixed to the sheet. The ring has a generally oval configuration similar to the generally oval configuration of the sheet of...http://www.google.com/patents/US20020026092?utm_source=gb-gplus-sharePatent US20020026092 - Ventricular restoration patchAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS20020026092 A1Publication typeApplicationApplication numberUS 09/860,699Publication dateFeb 28, 2002Filing dateMay 17, 2001Priority dateMay 1, 1998Also published asUS6544167, US6837247, US7594886, US7914438, US20030191538, US20050119520, US20100081869Publication number09860699, 860699, US 2002/0026092 A1, US 2002/026092 A1, US 20020026092 A1, US 20020026092A1, US 2002026092 A1, US 2002026092A1, US-A1-20020026092, US-A1-2002026092, US2002/0026092A1, US2002/026092A1, US20020026092 A1, US20020026092A1, US2002026092 A1, US2002026092A1InventorsGerald Buckberg, Constantine AthanasuleasOriginal AssigneeBuckberg Gerald D., Athanasuleas Constantine L.Export CitationBiBTeX, EndNote, RefManReferenced by (151), Classifications (11), Legal Events (6) External Links: USPTO, USPTO Assignment, EspacenetVentricular restoration patch
1. A ventricular patch to restore the ventricular architecture of the heart, comprising: a sheet of biocompatible material having a generally oval configuration; a continuous ring fixed to the sheet and having a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material, the ring defining a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring, the central generally oval region having a major axis and a minor axis, the ratio of the major axis to the minor axis being about 4:1. 2. The ventricular patch of claim 1, wherein the central generally oval region has a major axis of about 4 cm and a minor axis of about 1 cm. 3. A ventricular patch to restore the ventricular architecture of the heart, comprising: a sheet of biocompatible material having a generally oval configuration; a continuous ring fixed to the sheet and having a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material, the ring defining a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring, the central generally oval region having a major axis and a minor axis, the ratio of the major axis to the minor axis being at least about 2:1. 4. The ventricular patch of claim 3, wherein the central generally oval region has a major axis ranging from about 2 cm to about 8 cm and a minor axis ranging from about 0.5 cm to about 1 cm. 5. The ventricular patch of claim 3, wherein the ratio of the major axis to the minor axis is about 4:1. 6. The ventricular patch of claim 3, wherein the central generally oval region has a major axis of about 4 cm and a minor axis of about 1 cm. 7. A ventricular patch to restore the ventricular architecture of the heart, comprising: a sheet of biocompatible material having a generally oval configuration; a continuous ring fixed to the sheet and having a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material, the ring defining a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring, the central generally oval region having a major axis ranging from about 2 cm to about 8 cm and a minor axis ranging from about 0.5 cm to about 1 cm. 8. A ventricular patch to restore the ventricular architecture of the heart, comprising: a sheet of biocompatible material having a generally oval region with a major axis and a minor axis, the ratio of the major axis to the minor axis being about 4:1. 9. The ventricular patch of claim 8, wherein the central generally oval region has a major axis of about 4 cm and a minor axis of about 1 cm. 10. A ventricular patch to restore the ventricular architecture of the heart, comprising: a sheet of biocompatible material having a generally oval region with a major axis and a minor axis, the ratio of the major axis to the minor axis being greater than about 2:1. 11. The ventricular patch of claim 10, wherein the generally oval region has a major axis ranging from about 2 cm to about 8 cm and a minor axis ranging from about 0.5 cm to about 1 cm. 12. The ventricular patch of claim 10, wherein the ratio of the major axis to the minor axis is about 4:1. 13. The ventricular patch of claim 10, wherein the central generally oval region has a major axis of about 4 cm and a minor axis of about 1 cm. 14. A ventricular patch to restore the ventricular architecture of the heart, comprising: a sheet of biocompatible material having a generally oval region with a major axis ranging from about 2 cm to about 8 cm and a minor axis ranging from about 0.5 cm to about 1 cm. Description
BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] This invention relates generally to surgical methods and apparatus for addressing ischemic cardiomyopathy, and more specifically to methods and apparatus for restoring the architecture and normal function of a mammalian heart. [0003] 2. Discussion of the Prior Art [0004] The function of a heart in an animal is primarily to deliver life-supporting oxygenated blood to tissue throughout the body. This function is accomplished in four stages, each relating to a particular chamber of the heart. Initially deoxygenated blood is received in the right auricle of the heart. This deoxygenated blood is pumped by the right ventricle of the heart to the lungs where the blood is oxygenated. The oxygenated blood is initially received in the left auricle of the heart and ultimately pumped by the left ventricle of the heart throughout the body. It can be seen that the left ventricular chamber of the heart is of particular importance in this process as it is relied upon to pump the oxygenated blood initially through a mitral valve into and ultimately throughout the entire vascular system. [0005] A certain percentage of the blood in the left ventricle is pumped during each stroke of the heart. This pumped percentage, commonly referred to as the ejection fraction, is normally about sixty percent. It can be seen that in a heart having a left ventricular volume such as seventy milliliters, an ejection fraction of sixty percent would deliver approximately 42 milliliters of blood into the aorta. A heart with reduced left ventricular volume might have an ejection fraction of only 40% and provide a stroke volume of only 28 millimeters. [0006] Realizing that the heart is part of the body tissue, and the heart muscle also requires oxygenated blood, it can be appreciated that the normal function of the heart is greatly upset by clotting or closure of the coronary arteries. When the coronary arteries are blocked, an associate portion of the heart muscle becomes oxygen-starved and begins to die. This is clinically referred to as a heart attack. Ischemic cardiomyopathy typically occurs as the rest of the heart dilates in an attempt to maintain the heart's output to the body. [0007] As the ischemic area loses its contraction, the area of dilatation is restricted to the remaining muscle. The three regions of typical infarction include, 1) the anterior wall septum and anterolateral wall which are supplied by the anterior descending coronary artery; 2) the septum and inferior wall supplied by the left anterior artery and the right coronary artery which narrows due to the heart's elliptical shape; and 3) the lateral wall supplied by the circumflex artery which perfuses the lateral wall including the papillary muscle attachments to the ventricular wall. [0008] As the ischemic cardiomyopathy progresses, the various structures of the heart are progressively involved including the septum, the apex and the anterolateral wall of the left ventricle. Within a particular wall, the blood starvation begins at the inside of the wall and progresses to the outside of the wall. It can be seen that addressing ischemic cardiomyopathy shortly after the heart attack can limit the detrimental effects to certain elements of the heart structure, as well as the inner most thicknesses of the walls defining those structures. [0009] As a heart muscle is denied blood nourishment support, its ability to participate, let alone aid, in the cardiac pumping function, is greatly diminished and typically nil. Such muscle is commonly referred to as akinetic, meaning it does not move. In some cases the wall will form elastic scar tissue which tends to balloon in response to the pumping action. This muscle tissue is not only akinetic, in that it does not contribute to the pumping function, but it is in fact dyskinetic, in that it detracts from the pumping function. [0010] The akinetic tissue will, in addition to not contracting, cause cardiac enlargement due to dilatation or loss of its contractile capacity. The dilatation will widen, and thereby change the fiber orientation of the remaining muscle in the left ventricle. This will make the ventricle spherical, and change it from the normal elliptical form which optimizes contraction. [0011] The shape of the ventricle is normally elliptical or conical with an apex that allows a 60 degree fiber orientation of the muscle. This orientation ensures efficient development of intramuscular torsion to facilitate the pumping of blood. Compression of the left ventricular cavity occurs by torsional defamation which thickens the left ventricular wall. This increases progressively from the mid-ventricular wall to the apex. As a result, maintenance of the apical anchor is a central theme of cardiac contraction. [0012] Perhaps the most notable symptom of ischemic cardiomyopathy is the reduction in the ejection fraction which may diminish, for example, from a normal sixty percent to only twenty percent. This results clinically in fatigue, and inability to do stressful activities, that require an increase in output of blood from the heart. The normal response of the heart to a reduction in ejection fraction is to increase the size of the ventricle so that the reduced percentage continues to deliver the same amount of oxygenated blood to the body. By way of example, the volume of the left ventricle may double in size. Furthermore, a dilated heart will tend to change its architecture from the normal conical or apical shape, to a generally spherical shape. The output of blood at rest is kept normal, but the capacity to increase output of blood during stress (i.e., exercise, walking) is reduced. Of course, this change in architecture has a dramatic effect on wall thickness, radius, and stress on the heart wall. In particular, it will be noted that absent the normal conical shape, the twisting motion at the apex, which can account for as much as one half of the pumping action, is lost. As a consequence, the more spherical architecture must rely almost totally on the lateral squeezing action to pump blood. This lateral squeezing action is inefficient and very different from the more efficient twisting action of the heart. The change in architecture of the heart will also typically change the structure and ability of the mitral valve to perform its function in the pumping process. Valvular insufficiency can also occur due to dilatation. [0013] A major determinant of both cardiac oxygen requirement and efficiency is based upon a formula where stress or pressure is multiplied by the radius and divided by twice the thickness of the cardiac wall. Increasing stress reduces contractility or rejecting capacity, and raises energy requirements in the remaining contracting muscle. As the shape changes from elliptical to spherical, wall stress increases thereby demanding higher energy from the remaining cardiac muscle. This dilation, which occurs anteriorly, effects the septum, apex and anterolateral wall. Thus, the normally oval apex becomes more spherical due to 1) a loss of infarcted muscle, and 2) dilation of the remaining contracting muscle. [0014] Although the dilated heart may be capable of sustaining life, it is significantly stressed and rapidly approaches a stage where it can no longer pump blood effectively. In this stage, commonly referred to as congestive heart failure, the heart becomes distended and is generally incapable of pumping blood returning from the lungs. This further results in lung congestion and fatigue. Congestive heart failure is a major cause of death and disability in the United States where approximately 400,000 cases occur annually. [0015] Following coronary occlusion, successful acute reperfusion by thrombolysis, (clot dissolution) percutaneous angioplasty, or urgent surgery can decrease early mortality by reducing arrhythmias and cardiogenic shock. It is also known that addressing ischemic cardiomyopathy in the acute phase, for example with reperfusion, may salvage the epicardial surface. Although the myocardium may be rendered akinetic, at least it is not dyskinetic. Post-infarction surgical revascularization can be directed at remote viable muscle to reduce ischemia. However, it does not address the anatomical consequences of the akinetic region of the heart that is scarred. Despite these techniques for monitoring ischemia, cardiac dilation and subsequent heart failure continue to occur in approximately fifty percent of post-infarction patients discharged from the hospital. [0016] The distribution of heart failure is more common with occlusion of the left anterior descending coronary artery (LAD) due to its perfusion of the apex. But, this can also occur with inferior infarction, especially if there is inadequate blood supply to the apex due to 1) prior damage to the left anterior descending artery, or 2) inadequate blood supply due to stenosis or poor function. In general, the distribution of ischemia is 45% anterior, 40% inferior, and 15% circumflex. However, the incidence of congestive heart failure is more common in the anterior infarction. [0017] Various surgical approaches have been taken primarily to reduce the ventricular volume. This is also intended to increase the ejection fraction of the heart. In accordance with one procedure, viable muscle is removed from the heart in an attempt to merely reduce its volume. This procedure, which is typically accomplished on a beating heart, has been used for hearts that have not experienced coronary disease, but nevertheless, have dilated due to leaking heart valves. Other attempts have been made to remove the scarred portion of the heart and to close the resulting incision. This has also had the effect of reducing the ventricular volume. [0018] In a further procedure, a round, circular patch has been proposed for placement typically in the lateral ventricular wall. Unfortunately, providing the patch with a circular shape has allowed the dilated heart to remain somewhat enlarged with a thin and over-stressed wall section. The exact placement of the patch has been visually determined using only a visual indication where the typically white scar tissue meets the typically red normal tissue. Location of the patch has been facilitated in a further procedure where a continuous suture has been placed around the ventricular wall to define a neck for receiving the patch. The neck has been formed in the white scar tissue rather than the soft viable muscle. This procedure has relied on cardioplegia methods to stop the beating of the heart and to aid in suture placement. [0019] In the past, the patch has been provided with a fixed or semi-rigid wall which has prevented the muscle from becoming reduced to an apical anchor which facilitates the twisting motion. The patches have had a fixed planar configuration which have prevented the lateral muscle from coapting to form an apex. [0020] These surgical procedures have been met with some success as the ejection fraction has been increased, for example, from twenty-four percent to forty-two percent. However, despite this level of success, little attention has been paid to myocardial protection, the potential for monitoring the writhing action associated with apical structure, or the preferred structure for the patch. Failure to protect the heart during restoration of the segment has increased hospital mortality, morbidity, and irreversibly damaged some normal muscle needed to maintain the heart's output. SUMMARY OF THE INVENTION [0021] An aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval configuration, and a continuous ring fixed to the sheet. The ring has a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material. The ring defines a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring. The central generally oval region has a major axis and a minor axis. The ratio of the major axis to the minor axis is about 4:1. In a preferred implementation, the central generally oval region has a major axis of about 4 cm and a minor axis of about 1 cm. [0022] Another aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval configuration and a continuous ring fixed to the sheet. The continuous ring includes a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material, and defines a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring. The central generally oval region has a major axis and a minor axis. The ratio of the major axis to the minor axis is at least about 2:1. [0023] Another aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval configuration, and a continuous ring fixed to the sheet. The ring has a generally oval configuration similar to the generally oval configuration of the sheet of biocompatible material. The ring defines a central generally oval region of the patch inside the ring and a circumferential region of the patch outside of the ring. The central generally oval region has a major axis ranging from about 2 cm to about 8 cm and a minor axis ranging from about 0.5 cm to about 1 cm. [0024] A further aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval region with a major axis and a minor axis. The ratio of the major axis to the minor axis is about 4:1. In a preferred implementation, the generally oval region has a major axis of about 4 cm and a minor axis of about 1 cm. [0025] A still further aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval region with a major axis and a minor axis. The ratio of the major axis to the minor axis is at least about 2:1. [0026] A yet further aspect of the invention involves a ventricular patch to restore the ventricular architecture of the heart. The ventricular patch includes a sheet of biocompatible material having a generally oval region with a major axis ranging from about 2 cm to about 8 cm and a minor axis ranging from about 0.5 cm to about 1 cm. [0027] These and other features and advantages of the invention will become more apparent with a description of preferred embodiments and reference to the associated drawings.
DESCRIPTION OF THE DRAWINGS [0028] [0028]FIG. 1 is a perspective view of the abdominal cavity of a human body showing the heart in cross section; [0029] [0029]FIG. 2 is a front plan view of the heart showing coronary arteries which feed the septum, apex and lateral wall of the myocardium; [0030] [0030]FIG. 3 is a axial cross section view of the ventricular portions of the heart illustrating a dilated, generally spherical left ventricle; [0031] [0031]FIG. 4 is an anterior elevation view of the heart with an incision into the left ventricle through dyskinetic scar tissue; [0032] [0032]FIG. 5 is an anterior elevation view similar to FIG. 4 where the incision is made in marbled akinetic tissue; [0033] [0033]FIG. 6 is an anterior elevation view similar to FIG. 5 illustrating the incision made in normal-looking akinetic tissue; [0034] [0034]FIG. 7 is a axial cross section view of the left ventricle showing the surgeon's hand palpating the myocardium to define an imaginary circumferential line of separation between viable and akinetic tissue; [0035] [0035]FIG. 8 is a axial cross section view similar to FIG. 7 illustrating the palpating heart and a preferred zone of placement for a patch associated with the present invention; [0036] [0036]FIG. 9 is an anterior elevation view similar to FIG. 4 and illustrating placement of a Fontan stitch in the ventricular wall; [0037] [0037]FIG. 10 is an axial cross section view illustrating a Fontan neck created by the Fontan stitch; [0038] [0038]FIG. 11 is a side elevation view of the opening illustrated in FIG. 9 with the Fontan suture tightened to facilitate the natural oval formation of the opening; [0039] [0039]FIG. 12A is a plan view of sheet material included in one embodiment of the patch associated with the present invention; [0040] [0040]FIG. 12B is a cross section view taken along lines 12B-12B of FIG. 12A and illustrating the sheet material in a concave configuration; [0041] [0041]FIG. 13 is a top plan view of a ring associated with the patch of the present invention; [0042] [0042]FIG. 14 is a circumferential cross section taken along lines 14-14 of FIG. 13; [0043] [0043]FIG. 15 is a top plan view showing the sheet material and ring combined to form one embodiment of the patch of the present invention; [0044] [0044]FIG. 16 is a cross section view of the patch taken along lines 16-16 of FIG. 15; [0045] [0045]FIG. 17 is a cross section view similar to FIG. 12B and illustrating the sheet material in a convex configuration; [0046] [0046]FIG. 18 is a cross section view similar to FIG. 16 and illustrating the ring disposed on a concave surface of the sheet material; [0047] [0047]FIG. 19 is a cross section view similar to FIG. 18 and illustrating the ring sandwiched between two pieces of the sheet material; [0048] [0048]FIG. 20 is a cross section view similar to FIG. 19 and illustrating the ring sandwiched between two pieces of material, but having only a single layer in the center of the patch; [0049] [0049]FIG. 21 is an anterior elevation view similar to FIG. 11 and illustrating the placement of pledgeted, interrupted sutures engaging the patch in a remote location; [0050] [0050]FIG. 22A is an axial cross section view of the left ventricle illustrating the patch being moved along the interrupted sutures from the remote location to the Fontan neck; [0051] [0051]FIG. 22B is a perspective view similar to FIG. 21 and illustrating an alternative method for placement of interrupted sutures; [0052] [0052]FIG. 23 is an axial cross section view similar to FIG. 22 and illustrating the patch in its final disposition against the Fontan neck, and further illustrating use of the hemostatic rim to control bleeding; [0053] [0053]FIG. 24 is an axial cross section view of the ventricular portion of the heart, with the patch mounted in place, the ventricle wall restored to its apical configuration, and the lateral ventricular wall closed in overlapping relationship with the septum wall next to the patch; DESCRIPTION OF PREFERRED EMBODIMENTS AND BEST MODE OF THE INVENTION [0054] Abdominal portions of the human body are illustrated in FIG. 1 and designated by the reference numeral 10. The body 10 is merely representative of any mammalian body having a heart 12 which pumps blood containing nutrients and oxygen, to vitalize tissue in all areas of the body 10. Other organs of particular importance to this blood circulation process include the lungs 14 and 16, and the vasculature of the body 10 including arteries which carry blood away from the heart 12 and veins which return blood to the heart 12. [0055] The heart 12 typically includes four chambers, a right auricle 18, a right ventricle 21, a left auricle 23 and a left ventricle 25. In general, the auricles 18 and 23 are receiving chambers and the ventricles 21 and 25 are pumping chambers. Each of these chambers 18-25 is associated with a respective function of the heart 12. For example, it is the purpose of the right auricle 18 to receive the deoxygenated blood returning in the veins of the body 10, such as the femoral vein 27. From the right auricle 18, the deoxygenated blood passes into the right ventricle 21 from which it is pumped through a pulmonary artery 30 to the lungs 14 and 16. [0056] Within the lungs 14 and 16, the deoxygenated blood is reoxygenated and returned to the left auricle 23 of the heart 12 through a pulmonary vein 32. From this chamber, the oxygenated blood passes through a mitral valve 34 into the left ventricle 25. With each beat of the heart 12, the left ventricle 25 contracts pumping the oxygenated blood into the arteries of the body, such as the femoral artery 36. [0057] The shape of the normal heart 12 is of particular interest as it dramatically affects the way that the blood is pumped. It will be noted, for example, that the left ventricle 25, which is the primary pumping chamber, is somewhat elliptical, conical or apical in shape in that it is longer than it is wide and descends from a base 35 with a decreasing cross-sectional circumference, to a point or apex 37. The left ventricle 25 is further defined by a lateral ventricle wall 38, and a septum 41 which extends between the atrium 18, 23, and between the ventricles 21, 25. The mitral valve 34 is situated in an antero-ventricular junction 42 which extends laterally between the atrium 18, 23, and ventricles 21, 25. The “base” of the inferior muscle is also in this general location. This wide base 35 extends to the apex 37 on the inferior cardiac surface. In the area of the base 35, the muscle is relatively flat or slightly spherical compared to the curvilinear form in the anterior wall. The muscle fiber orientation is maintained at approximately 60 degrees from base 35 to apex 37 to maintain the torsional gradient which facilitates ejection. This orientation of fibers changes to accentuate ejection, with less twisting at the base 35 and more twisting at the apex 37. [0058] On the backside, the heart 12 has an inferior wall 44 that is not curved or linear, but rather flat or slightly spherical in configuration. This inferior wall 44 extends from the antero-ventricular junction 42, at the wide area of the heart, toward the apex 37. [0059] The pumping of the blood from the left ventricle 25 is accomplished by two types of motion. One of these motions is a simple squeezing motion which occurs between the lateral wall 38 and the septum 41 as illustrated by the arrows 43 and 45, respectively. The squeezing motion occurs as a result of a thickening of the muscle fibers in the myocardium. This compresses the blood in the ventricle chamber 25 and ejects it into the body 10. The thickening is reduced in diastole (before the heart is contracting) and increased in systole (when the heart is ejecting). This is seen easily by echocardiogram, and can be routinely measured. [0060] In addition to the squeezing, there is a twisting of fibers that results in thickening of the ventricular wall, and shortening of the muscle from the base 35 to the apex 37. This is the predominant aspect of left ventricle systole. The muscle untwists after twisting (when the heart is prepared to fill) during the first third of ventricular relaxation. [0061] The twisting or writhing motion which begins at the apex 37 and rises toward the base 35, as shown by the arrow 47. The rising writhing motion occurs because the heart muscle fibers run in a circular or spiral direction around the heart 12. When these fibers constrict, they cause the heart to twist initially at the small area of the apex 37, but progressively and ultimately to the wide area of the base 35. [0062] Recent studies by MRI show that twisting in systole accounts for approximately 80% of stroke volume, while untwisting (in diastole) accounts for 80% of left ventricle filling. This twisting and untwisting occurs in the same muscle segments, as the ventricle shortens during ejection and lengthens after blood is ejected. [0063] The amount of blood pumped from the left ventricle 25 divided by the amount of blood available to be pumped is referred to as the ejection fraction of the heart 12. Generally, the higher the ejection fraction the more healthy the heart. A normal heart, for example, may have a total volume of one hundred milliliters and an ejection fraction of sixty percent. Under these circumstances, 60 milliliters of blood are pumped with each beat of the heart 12. It is this volume of blood in the normal heart of this example, that is pumped with each beat to provide nutrients including oxygen to the muscles and other tissues of the body 10. [0064] The muscles of the body, of course, include the heart muscle or myocardium which defines the various chambers 18-25 of the heart 12. This heart muscle also requires the nutrients and oxygen of the blood in order to remain viable. With reference to FIG. 2, it can be seen that the anterior or front side of the heart 12 receives oxygenated blood through a common artery 58 which bifurcates into a septal artery branch 52, which is directed toward the septum 41, and an anterior descending artery 54 which is directed toward the apex 37 and the lateral ventricle wall 38. [0065] The inferior wall 44 is supplied by the right coronary artery which also perfuses the septum 41. This wall 44 forms a triangle which extends from the base 35 to the apex 37. Consequently, the apex 37 is supplied by both the anterior descending artery and the right coronary artery. [0066] When a blockage occurs in one of these coronary arteries, that portion of the heart muscle which is fed by the blocked artery no longer receives the oxygen needed to remain viable. These blockages typically occur in the common artery 50 and in the septal artery branch 52. When the common artery is involved, the septum 41, apex 37 and lateral wall 38 all become ischemic or oxygen deprived. When only the septal artery branch 52 is involved, the ischemic symptoms are limited primarily to the septum 41 and the apex 37. In this latter case, the septum 41 is almost always affected, the apex 31 is usually affected, and the lateral wall 38 is sometimes affected. [0067] As the ischemia progresses through its various stages, the affected myocardium dies losing its ability to contribute to the pumping action of the heart. The ischemic muscle is no longer capable of contracting so it cannot contribute to either squeezing or the twisting motion required to pump blood. This non-contracting issue is said to be akinetic. In severe cases the akinetic tissue, which is not capable of contracting, is in fact elastic so that blood pressure tends to develop a bulge or expansion of the chamber. This is particularly detrimental as the limited pumping action available, as the heart 12 loses even more of its energy to pumping the bulge instead of the blood. [0068] The body's reaction to ischemic infarction is of particular interest. The body 10 seems to realize that with a reduced pumping capacity, the ejection fraction of the heart is automatically reduced. For example, the ejection fraction may drop from a normal sixty percent to perhaps twenty percent. Realizing that the body still requires the same volume of blood for oxygen and nutrition, the body causes its heart to dilate or enlarge in size so that the smaller ejection fraction pumps about the same amount of blood. As noted, a normal heart with a blood capacity of seventy milliliters and an ejection fraction of sixty percent would pump approximately 42 milliliters per beat. The body seems to appreciate that this same volume per beat can be maintained by an ejection fraction of only thirty-percent if the ventricle 25 enlarges to a capacity of 140 milliliters. This increase in volume, commonly referred to as “remodeling” not only changes the volume of the left ventricle 25, but also its shape. The heart 12 becomes greatly enlarged and the left ventricle 25 becomes more spherical in shape losing its apex 37 as illustrated in FIG. 3. In this view, the stippled area of cross section shows the ischemic or infracted region of the myocardium. [0069] On the level of the muscle fibers, it has been noted that dilation of the heart causes the fibers to reorient themselves so that they are directed away from the inner heart chamber containing the blood. As a consequence, the fibers are poorly oriented to accomplish even the squeezing action as the lines of force become less perpendicular to the heart wall. It will be noted that this change in fiber orientation occurs as the heart dilates and moves from its normal elliptical shape to its dilated spherical shape. The spherical shape further reduces pumping efficiency since the fibers which normally encircle the apex to facilitate writhing are changed to a more flattened formation as a result of these spherical configurations. The resulting orientation of these fibers produce lines of force which are also directed laterally of the ventricle chamber 25. Thus, the dilatation and resulting spherical configuration greatly reduce contraction efficiency. It also raises myocardial oxygen demands as torsional defamation (strain) increases. When a remote muscle is supplied by a non-occluded vessel under stress, the remote muscle tends to contract inefficiently. [0070] Although the remodeling of the heart 12 by the body 10 helps in maintaining the blood flow, it places the heart wall under considerable stress which eventually can result in congestive heart failure. While myocardial ischemia or infarction is the primary cause of death and disability in this country, congestive heart failure is certainly the secondary cause with over 400,000 cases reported annually. It is this post-infarction congestive heart failure which is a primary focus of the present invention. [0071] As noted, successful acute reprefusion by thrombolysis, percutaneous angioplasty, or urgent surgery can decrease early mortality by reducing arrhythmia and cardiogenic shock. These procedures applied in the early stages of ischemia can also aid in salvaging the epicardial surface of the myocardium and thereby prevent akinetic tissue from becoming dyskinetic. Notwithstanding these known methods of intervention, cardiac dilation and subsequent congestive heart failure occur in approximately fifty percent of the post-infarction patients. [0072] Ventricular volume is not excessive or >100 ml/m2 left ventricular end systolic volume. The akinetic lateral wall may contain non-functional (contractile tissue) that is hibernating. This indicates viable tissue that improves contraction several months after complete revascularization or when ventricular volume is reduced to produce a more normal ventricular contour (i.e. ellipse). This recovery after revascularization can occur only when ventricular volume is not very large, or the left ventricular end systolic volume index >100 ml/m2. This aspect of recovery of akinetic hibernating muscle is potentially important when the ventricular shape is changed surgically to go from a sphere (failing heart) to a conical or apical (more normal configuration) contour. [0073] The procedure of the present invention addresses the effects of myocardial infarction using a cardioprotective approach to restore the geometry of the left ventricle. This is not a “remodeling” procedure automatically produced by the body 10, nor a “reconstructive” procedure which leaves the heart with other than a normal geometry. Rather, this is a procedure which attempts to “restore” the normal geometry, and particularly the apical configuration of the left ventricle 25. The procedure reduces the volume of the left ventricle 25, but also increases the percentage of the ventricle wall which is viable. This greatly increases the ejection fraction of the heart and significantly reduces heart stress. [0074] With a primary purpose of reducing the left ventricle volume, the intent of the procedure initially is to remove that portion of the wall which is not capable of contracting. This, of course, includes the scarred dyskinetic segments, which are easy to visualize, but may also include akinetic segments, which do not contract despite their normal appearance. [0075] An incision 61 is cut into the myocardial wall of the dilated heart 12 as illustrated in FIG. 4. If the surrounding tissue is dyskinetic, it will typically be formed entirely of thin, elastic scar tissue. It is the elasticity of this scar tissue which causes the detrimental ballooning or bulging effects previous discussed. [0076] In some cases, the tissue surrounding the incision 61 will be somewhat marbled as illustrated in FIG. 5 with patches of both scar tissue 63 and viable red tissue 65. This marbled tissue is often characterized by trabeculae 67 which form ridges along the inner surface or endothelium of the wall. In spite of the presence of some viable tissue 65, these marbled walls of the heart 12 may nevertheless be akinetic. [0077] With reference to FIG. 6, it is apparent that the akinetic portion of the myocardium may even appear to be viable with an absence of white scar tissue and the presence of a full red color. Nevertheless, these portions are akinetic and offer no positive effect to the pumping process. [0078] Given these factors, it is apparent that a determination as to where the akinetic portions begin and end cannot be a visual determination as relied on by the prior art. Although the visual appearance may be of some value in this determination, ultimately, one must palpate the tissue as illustrated in FIG. 7. Note that this emphasizes the importance of performing the restorative surgery on a beating heart. By palpating the myocardial wall, one can feel where the contractions of the lateral ventricular wall 38 and the septum 41 begin and end. Without regard for color or other properties visually distinguishable, the palpating will usually indicate viable tissue on one side of an imaginary circumferential line 70, with akinetic and dyskinetic tissue on the other side of the imaginary line 70. As described in greater detail below, a patch 72 will ultimately be positioned relative to this imaginary circumferential line 70 not only to reduce the volume of the left ventricle 25 but also to define that reduced volume with a larger percentage of viable heart muscle. [0079] After the preferred location of the patch 72 has been determined relative to the circumferential line 70, a continuous Fontan stitch 74 can be placed in proximity to the line 70 as illustrated in FIG. 9. This stitch 74 produces an annular protrusion 76 which forms a neck 78 relative to the imaginary line 70. This neck 78 initially may have a round circular configuration as illustrated in FIG. 9. However, as the suture 74 is tightened, the musculature of the myocardium will form a natural oval shape as illustrated in FIG. 1. It is this oval-shaped neck 78, formed by the Fontan stitch 74, which in its natural ovoid shape is particularly adapted to receive the patch 72 of the present invention. [0080] Providing the patch 72 with a configuration complimentary to the ovoid shape of the Fontan stitch 74 is believed to be of particular importance and advantage to the present invention. In the past, patches of a round, circular form were used. This form maintained the fibers in their less efficient transverse orientation. This was especially true of rigid and semi-rigid patches. As a result, the fiber contraction continued to be very inefficient. Providing the patch with an oval configuration restores the apex 37 or elliptical form of the heart 12. On a muscle fiber level, the fibers are directed back to the more efficient 60 degree orientation which produces lines of force more perpendicular with respect to the heart wall 38. This reorientation of the lines of forces greatly increases contraction efficiency. [0081] Of perhaps equal concern is the use of semi-rigid or rigid rings on the patches of the past. By keeping the edges of the patch in a rigid configuration, these rings have inhibited the natural tendency of the heart to form the remaining muscle into a normal apical chamber. [0082] Construction of various embodiments of the patch 72 are discussed with reference to FIGS. 12A-20. In the plan view of FIG. 12A, a sheet material 81 is illustrated to have the shape of an ellipse with a major axis 83 between 30 and 50 millimeters and a minor axis 85 between 20 and 30 millimeters. It is contemplated that the sheet material 81 can be provided in two sizes, such as 20�30 millimeters and 30�40 millimeters. [0083] The sheet material 81 may be formed, for example, from Dacron (Hemoshield), or polytetrafluroethylene (Gortex). However in a preferred embodiment, the sheet material 81 is formed of autologous pericardium, or some other fixed mammalium tissue such as bovine or porcine pericardium. Importantly, the sheet material 81 is preferably sized and configured with a shape similar to that of the Fontan neck 78 as illustrated in FIG. 11. As noted, this shape is non-circular and preferably oval. [0084] The sheet material 81 can have a generally flat planar configuration, or can be shaped as a section of a sphere. The spherical shape can be achieved as illustrated in FIG. 12B by fixing the pericardium while it is stretched over a spherical die to form a concave surface 91. [0085] In addition to the sheet material 81, the patch 72 also preferably includes a ring 87 which will typically have a toroidal configuration with a circumferential cross section that is circular, as shown in FIG. 13. The ring will typically be formed of a plastic graft material that can also be made of curled autogenous tissue such as fascia or pericardium. In general, the ring 87 can be formed from any biocompatible material having a degree of flexibility suitable to prevent interference with the normal contractions of the heart 12. [0086] The circumferential cross section view of FIG. 14 illustrates that the ring 87 may be enclosed in a tubular sheath 90 which may be formed from woven Dacron, and incorporated to promote tissue ingrowth to the patch 72. [0087] The ring 87 will generally have a non-circular shape which may be similar to but smaller than the shape of the material 81. Providing the ring 87 with a shape similar to the material 81 will enable the ring 87 to be attached to the material 81 as illustrated in FIGS. 15 and 16 with a body or internal oval 91 of the patch disposed within the ring 87, and a circumferential rim or flange 93 disposed outwardly of the ring 87. The rim 93 will preferably have a constant width around its circumference. This width will typically be in a range between 5 and 10 millimeters. [0088] The internal oval 91 disposed within the ring 87 preferably has a substantially oval configuration with a major axis 92 and a minor axis 94. In an alternative preferred embodiment of the invention, the body or internal oval 91 of the patch disposed within the ring 87 has a major axis of about 40 mm (4 cm) and a minor axis of about 10 mm (1 cm). The ratio of the major axis 92 to the minor axis 94 in this embodiment is about 4:1 or 4. The inventors have determined that a more linear, longitudinally elongated internal oval or body 91 makes the ventricular shape, after patch placement, more elliptical, making resulting fiber orientation oblique and directed towards a conical apex 37. Although the preferred major axis to minor axis ratio in this embodiment of the patch is about 4:1, ratios greater than 2:1 are also desirable for making the apex 37 more elliptical. The major axis 92 preferably may vary between 20 mm (2 cm) and 80 mm (8 cm) and the minor axis preferably may vary between 5 mm (0.5 cm) and 10 mm (1 cm). [0089] Many variations on the patch 72 will be apparent from the foregoing discussion. For example, as illustrated in FIG. 17, the sheet material 81 can be provided with a convex surface 95 facing the left ventricle 25 rather than the concave surface illustrated in FIG. 13. As illustrated in FIGS. 16 and 18, the ring 87 can be disposed on either the interior or exterior side of the material 81. [0090] With reference to FIG. 18, the ring 87 can be attached to the material 81 by adhesive or by stitches 97 passing over the ring 87 and through the material 81. Alternatively, with reference to FIG. 19, the ring 87 can be sandwiched between two pieces of the sheet material. In this case, a second piece of the sheet material 99 can be positioned on the side of the ring 87 opposite to the sheet material 81. Appropriate sutures extending around the ring 87 and through the materials 81 and 99 will sandwich the ring and maintain it in the preferred position. With reference to FIG. 20, the second piece of material 99 can be formed as a circle with an inner diameter 100 less than that of the ring 87, and an outer diameter 102 generally equal to that of the material 81. [0091] It will be appreciated that many variations on these preferred embodiments of the patch 82 will be apparent, each having a generally non-circular sheet material, such as the material 81, and perhaps a somewhat flexible toroid or oval ring 87. [0092] In a preferred method for placing the patch 72, interrupted sutures 105 can be threaded through the Fontan neck 78 as illustrated in FIG. 21. Where the tissue is soft, the sutures 105 can be looped through pledgets 110 on the interior side of the neck 78 with the free ends of the sutures 105 extending through the exterior side of the neck 78. These free ends, emanating from progressive positions around the circumferential neck 78, are passed in complementary positions through the body of the patch 72 which is initially positioned remotely of the neck 78 as illustrated in FIG. 21. Since the Fontan stitch 74 may be applied to normal (although akinetic) tissue, the pledgets 110 are preferred to insure that the sutures 105 are well anchored in the neck 78. [0093] Another method for placement of the interrupted patch suture is illustrated in FIGS. 22A and 22B. In this view, which is similar to FIG. 21, interrupted sutures 111 are directed through the entire ventricular wall 38 and exit the wall 38 in proximity to the protrusion 76 which forms the Fontan neck 78. These sutures 111 can also be anchored in a pledged strip 113 disposed on the outer surface of the heart 12 to further enhance the anchoring of these sutures 111. [0094] When all of the interrupted sutures 105 have been placed around the circumference of the neck 87, the patch 72 can be moved from its remote location along the sutures 105 and into proximity with the oval neck 78. This step is illustrated in FIG. 22A where the patch 72 is embodied with the concave surface 90 facing the neck 78 and with the ring 87 disposed outwardly of the material 81. After the patch 72 has been moved into an abutting relationship with the neck 78, the interrupted sutures 105 can be tied as illustrated in FIG. 23. [0095] Having closed the left ventricular cavity 25 with the patch 72, one may proceed to address any bleeding which may have resulted from placement of the Fontan stitch 74 or the sutures 105, especially from the region of the septum 41. Such bleeding, illustrated by the reference numeral 112 in FIG. 23, will typically occur in close proximity to the neck 78 and beneath the region covered by the rim or flange 93 associated with the material 81 of the patch 72. This bleeding can normally be stopped by merely placing a suture through the ventricular wall 38 and the rim 93 at the point of bleeding. A pledget 114 can be used to tie the suture 112 with the rim 93 closely held against the bleeding wall 38. This reinforcing stitch, acting in combination with the rim 93 of the patch 72, will usually stop any bleeding associated with the sutures. [0096] In the embodiment of the patch where the internal oval 91 is more linear or longitudinally elongated (e.g., 10�40 mm internal oval), the method of patch closure produces an oblique line. The lower margin is at the apex, adjacent to the right or apical side of the anterior papillary muscle. The closure extends from the lateral ventricle toward the septum, that progressed along an intraventricular line to approximately 2 cm below the aortic valve on the septum. The open width of the patch is ˜1 cm (within the oval) so that the suture which runs along the patch margins can be used for hemostasis. [0097] With the patch 72 suitably placed, the operative site can be closed by joining the myocardial walls in a vest-over-pants relationship as illustrated in FIG. 24. Care should be taken not to distort the right ventricle 21 by folding the septum wall 41 over the ventricular wall 38. Alternatively, the lateral wall 38 can be disposed interiorly of the septum wall 41 so a majority of the force on the patch 72 is diverted to the lateral wall 38. These walls 38 and 41 can be overlapped in close proximity to the patch 72 in order to avoid creating any cavity between the patch 72 and the walls 38, 41. When air evacuation is confirmed by transesophageal echo, the patient can be weaned off bypass usually with minimal, if any, inotropic support. Decanulasation and closure is routine. [0098] [0098]FIG. 24 is positioned in proximity to FIG. 3 in order to illustrate the dramatic difference between the pre-operative dilated heart of FIG. 3 and the post-operative apical heart of FIG. 24. For comparison it will again be noted that the dilated heart of FIG. 3 might typically have a left ventricular volume of 140 milliliters which might produce a blood flow of 42 milliliters with an ejection fraction of 30%. Comparing this with the postoperative heart of FIG. 24, it can be seen initially that the ventricular volume is reduced for example to 90 milliliters. The percentage of viable heart wall as opposed to akinetic heart wall is greatly increased thereby providing an increase in the ejection fraction, for example from thirty percent to forty-five percent. This combination results in a pumped blood volume of about 40 milliliters with each beat of the heart 12. [0099] These structural changes are somewhat quantitative in consideration. But a further advantage, qualitative in nature, is also associated with the present procedure. It will be noted that this restorative procedure provides the heart 12 with a more natural apical configuration which facilitates the writhing action discussed with reference to the arrow 47 in FIG. 1. Thus, not only is the normal size of the heart achieved, but the restoration procedure also achieves a normal heart operation. In combination, the patch 72 and the resulting procedure significantly reduce the long term effects of myocardial ischemia and overcome many of the causes associated with congestive heart failure. [0100] It may be found that muscle function will be restored to some remote areas following the altered ventricular architecture. Although not fully understood, it is believed that this restoration procedure improves remote segmental myocardial contractility by reducing the wall tension and stress in the myocardium due to a reduction in ventricular volume. The stress equation states that Stress = P � R 2  h [0101] where [0102] P is blood pressure; [0103] R is radius of the heart wall; and [0104] h is wall thickness. [0105] The late recovery of hibernating muscle, which may be present in akinetic muscle whose fiber orientation is directed helically (toward the newly created apex). This progressive shape change may provide further improvement in contractile function several months after restoration. Reducing the ventricular volume decreases the radius, increases the thickness, and thereby reduces wall stress. This improves the myocardial oxygen supply/demand relationship, but may also revive the contractibility of otherwise normal but previously stressed myocardium. At the very least, the reduced stress on the heart 12 is relieved along with any potential for congestive heart failure. [0106] A further advantages of this procedure relates to the incision 61 in the left ventricle 25 which also provides access to the mitral valve 34. Replacing this mitral valve 34 through the left ventricle 25 is much simpler than the present intra-atrial replacement procedure. Coronary artery bypass grafts also can be more easily accommodated intraoperatively. As a result, all of these repairs can be undertaken with greater simplicity and reduced time. While blood cardioplegia may be advantageously used for revascularization and valvular procedures, it would appear that the restorative procedure is best accomplished with continuous profusion of the beating open heart for cardiac protection. [0107] Placement of patch 70 can be further enhanced by providing in the patch kit a plurality of sizing disks which can be individually held in proximity to the Fontan neck in order to determine appropriate patch size. Similar discs, triangular in shape may be used for the inferior restoration process. The disks might have a generally planar configuration, and of course, would vary in size. Each disk might have a centrally located handle extending from the planar disk for ease of use. The patch 72 could be removably mounted on a holder also including a disk, on which the patch is mounted, and an elongate handle extending from the disk to facilitate placement. [0108] As further support for the restoration procedure, a special suture needle is contemplated which has a proximal end and a distal end. The proximal end is generally straight and accounts for more than half of the length of the needle. The distal end is curved along a relatively large radius facilitating initial penetration of the thick heart wall. With this configuration, the needle can be easily introduced through the thick myocardium, but then pulled along a generally straight path as it is removed interiorly of the ventricle. [0109] The goal of these procedures is to restore the heart 12 to its normal size, shape and function. This includes restoring the conical apex of the heart in order to achieve the writhing pumping action. The nonfunctioning segmental ventricular myocardium is excluded and replaced with a patch so that the only akinetic wall of the ventricle is that defined by the small patch area. Not only is visual assessment enhanced, but more importantly, palpation affords the surgeon the ability to carefully and accurately determine the circumferential line of separation between the contracting and noncontracting muscle. This determination is achieved although the muscle may have normal color and may not contain either circular or trabecular scar tissue. [0110] It is believed that cardioplegia arrest maybe deleterious to ventricular function in the open ventricle because of nonuniform flow distribution. By avoiding this cardioplegia arrest and operating on a beating heart, aortic cross clamping as well as the use of inter-aortic balloons and ventricular assist devices can be avoided. Patch placement can be intraoperatively adjusted guided by echo or radio nucleotide data. Placement of the patch is further simplified by creation of the Fontan neck 78, and use of interrupted felt or pericardial pledgeted sutures 105. The circumferential rim 93 associated with the patch 72 facilitates bleeding control without distortion of the patch 72. Finally, using a vest-over-pants closure of the excluded ventricle obliterates dead space and provides security against patch leaks and resultant expansion between the site of closure of the ejecting ventricle with the patch, and where the excluded muscle is closed by the excluded ventricle. [0111] If the patch has a conical or elliptical contour, the pants-over-vest closure is excluded, so that progressive recovery of potentially hibernating muscle (previously akinetic) can occur so that the muscle itself forms the apex. The pants-over-vest closure may prevent this, and that is the reason for excluding it. [0112] Within these wide objectives and parameters, there will be variations on the structure of the patch and the methods of restoration. Although the non-circular configuration of the sheet material and ring are believed to be critical, the shape of the patch 72 may vary widely to provide the best anatomical fit with the natural shape of the ventricle 25. The sheet material 81 may be composed of a variety of materials, both natural and artificial. These materials may be woven or nonwoven to achieve a desired structure for the sheet material 81. The ring 87 may similarly be formed from a variety of materials and provided with a variety of shapes in order to add structure to the patch 72 without interfering with the normal contractions of the heart 12. Variations of the steps of the associated restoration method might include mounting the patch with a convex surface facing the ventricular cavity, use of tissue adhesives are also contemplated for attaching sealing and otherwise fixing the patch 72 to the Fontan neck 78. [0113] Given these wide variations, which are all within the scope of this concept, one is cautioned not to restrict the invention to the embodiments which have been specifically disclosed and illustrated, but rather encouraged to determine the scope of the invention only with reference to the following claims. Referenced byCiting PatentFiling datePublication dateApplicantTitleUS6681773May 24, 2001Jan 27, 2004Chase Medical, Inc.Kit and method for use during ventricular restorationUS6702763May 24, 2001Mar 9, 2004Chase Medical, L.P.Sizing apparatus and method for use during ventricular restorationUS6723038Oct 6, 2000Apr 20, 2004Myocor, Inc.Methods and devices for improving mitral valve functionUS6746471May 25, 2001Jun 8, 2004Myocor, Inc.Transventricular implant tools and devicesUS6764510Jan 9, 2002Jul 20, 2004Myocor, Inc.Devices and methods for heart valve treatmentUS6808488May 2, 2002Oct 26, 2004Myocor, Inc.External stress reduction device and methodUS6837247Apr 8, 2003Jan 4, 2005Correstore, Inc.Method of using ventricular restoration patchUS6959711Jun 5, 2003Nov 1, 2005Chase Medical, L.P.Kit and method for use during ventricular restorationUS6994093May 24, 2001Feb 7, 2006Chase Medical, L.P.Ventricular restoration shaping apparatus and method of useUS7279007Aug 1, 2002Oct 9, 2007Cardioklnetix, Inc.Method for improving cardiac functionUS7303526 *Aug 1, 2002Dec 4, 2007Cardiokinetix, Inc.Device for improving cardiac functionUS7399271Jan 9, 2004Jul 15, 2008Cardiokinetix, Inc.Ventricular partitioning deviceUS7513867Jul 16, 2003Apr 7, 2009Kardium, Inc.Methods and devices for altering blood flow through the left ventricleUS7582051Jun 10, 2005Sep 1, 2009Cardiokinetix, Inc.Peripheral seal for a ventricular partitioning deviceUS7594886Jan 3, 2005Sep 29, 2009Correstore LlcMethod of using ventricular restoration patchUS7648532Jan 3, 2006Jan 19, 2010Septrx, Inc.Tissue distention device and related methods for therapeutic interventionUS7666224Jul 7, 2005Feb 23, 2010Edwards Lifesciences LlcDevices and methods for heart valve treatmentUS7674222Mar 9, 2010Cardiokinetix, Inc.Cardiac device and methods of use thereofUS7678145 *Jul 1, 2005Mar 16, 2010Edwards Lifesciences LlcDevices and methods for heart valve treatmentUS7695425Feb 17, 2004Apr 13, 2010Edwards Lifesciences LlcHeart wall tension reduction apparatus and methodUS7722523Jul 9, 2002May 25, 2010Edwards Lifesciences LlcTransventricular implant tools and devicesUS7749249Jul 6, 2010Kardium Inc.Method and device for closing holes in tissueUS7762943Mar 3, 2004Jul 27, 2010Cardiokinetix, Inc.Inflatable ventricular partitioning deviceUS7766812Apr 14, 2006Aug 3, 2010Edwards Lifesciences LlcMethods and devices for improving mitral valve functionUS7837610Aug 2, 2006Nov 23, 2010Kardium Inc.System for improving diastolic dysfunctionUS7862500Jun 10, 2005Jan 4, 2011Cardiokinetix, Inc.Multiple partitioning devices for heart treatmentUS7883539Apr 23, 2002Feb 8, 2011Edwards Lifesciences LlcHeart wall tension reduction apparatus and methodUS7887477 *Feb 15, 2011Cardiokinetix, Inc.Method of improving cardiac function using a porous membraneUS7897086Mar 1, 2011Cardiokinetix, Inc.Method of making a laminar ventricular partitioning deviceUS7914438Mar 29, 2011Correstore LlcVentricular restoration patchUS7976455Jul 12, 2011Cardiokinetix, Inc.Inflatable ventricular partitioning deviceUS7981020Jun 5, 2008Jul 19, 2011Edwards Lifesciences LlcTransventricular implant tools and devicesUS8070805Jan 25, 2010Dec 6, 2011Edwards Lifesciences LlcDevices and methods for heart valve treatmentUS8092367Jan 10, 2012Mardil, Inc.Method for external stabilization of the base of the heartUS8128553Dec 12, 2006Mar 6, 2012Mardil, Inc.Method and apparatus for external stabilization of the heartUS8192478Jun 5, 2012Cardiokinetix, Inc.System for improving cardiac functionUS8226711Jul 24, 2012Edwards Lifesciences, LlcValve to myocardium tension members device and methodUS8246671Aug 25, 2008Aug 21, 2012Cardiokinetix, Inc.Retrievable cardiac devicesUS8257428Sep 4, 2012Cardiokinetix, Inc.System for improving cardiac functionUS8267852Jul 8, 2010Sep 18, 2012Edwards Lifesciences, LlcHeart wall tension reduction apparatus and methodUS8313533 *Nov 20, 2012Aesculap AgSheathing for restoring the function of valves of varicose veins and use of the sheathing in surgeryUS8337524Dec 25, 2012Kardium Inc.Method and device for closing holes in tissueUS8377114Apr 10, 2009Feb 19, 2013Cardiokinetix, Inc.Sealing and filling ventricular partitioning devices to improve cardiac functionUS8388672Apr 10, 2009Mar 5, 2013Cardiokinetix, Inc.System for improving cardiac function by sealing a partitioning membrane within a ventricleUS8398537Jul 24, 2009Mar 19, 2013Cardiokinetix, Inc.Peripheral seal for a ventricular partitioning deviceUS8439817May 14, 2013Edwards Lifesciences, LlcChordae capturing methods for stress reductionUS8449605May 28, 2013Kardium Inc.Method for anchoring a mitral valveUS8460173Jun 11, 2013Edwards Lifesciences, LlcHeart wall tension reduction apparatus and methodUS8500790Jun 4, 2012Aug 6, 2013Cardiokinetix, Inc.Retrievable cardiac devicesUS8500795Aug 25, 2008Aug 6, 2013Cardiokinetix, Inc.Retrievable devices for improving cardiac functionUS8506624Dec 2, 2011Aug 13, 2013Edwards Lifesciences, LlcDevices and methods for heart valve treatmentUS8529430May 29, 2008Sep 10, 2013Cardiokinetix, Inc.Therapeutic methods and devices following myocardial infarctionUS8579798Jun 5, 2008Nov 12, 2013Edwards Lifesciences, LlcExternal cardiac stress reduction methodUS8657873 *May 7, 2007Feb 25, 2014Cardiokinetix, Inc.System for improving cardiac functionUS8672827Jan 21, 2010Mar 18, 2014Cardiokinetix, Inc.Cardiac device and methods of use thereofUS8672998Apr 29, 2013Mar 18, 2014Kardium Inc.Method for anchoring a mitral valveUS8747454May 7, 2007Jun 10, 2014Cardiokinetix, Inc.System for improving cardiac functionUS8758395Jul 19, 2005Jun 24, 2014Septrx, Inc.Embolic filtering method and apparatusUS8790242Oct 26, 2010Jul 29, 2014Cardiokinetix, Inc.Ventricular volume reductionUS8795383 *Jun 13, 2005Aug 5, 2014Alfredo AlvaradoLaparoscopic inguinal hernia prosthesisUS8827892Aug 22, 2013Sep 9, 2014Cardiokinetix, Inc.Therapeutic methods and devices following myocardial infarctionUS8840665Jun 10, 2011Sep 23, 2014Liventa Bioscience, Inc.Method of tendon repair with amnion and chorion constructsUS8940002Sep 28, 2011Jan 27, 2015Kardium Inc.Tissue anchor systemUS8961617Mar 8, 2013Feb 24, 2015Liventa Bioscience, Inc.Amnion and chorion constructs and uses thereof in abdominal surgeryUS9017394Jul 30, 2013Apr 28, 2015Cardiokinetix, Inc.Retrievable cardiac devicesUS9039597Jun 13, 2014May 26, 2015Cardiokinetix, Inc.Ventricular volume reductionUS9050066May 20, 2011Jun 9, 2015Kardium Inc.Closing openings in anatomical tissueUS9072511Mar 15, 2012Jul 7, 2015Kardium Inc.Medical kit for constricting tissue or a bodily orifice, for example, a mitral valveUS9078660Sep 29, 2010Jul 14, 2015Cardiokinetix, Inc.Devices and methods for delivering an endocardial deviceUS9192468Jan 23, 2014Nov 24, 2015Kardium Inc.Method for anchoring a mitral valveUS9198757Jul 7, 2009Dec 1, 2015Edwards Lifesciences, LlcMethods and devices for improving mitral valve functionUS9204964Jun 13, 2013Dec 8, 2015Kardium Inc.Medical device, kit and method for constricting tissue or a bodily orifice, for example, a mitral valveUS9332992Mar 14, 2013May 10, 2016Cardiokinetix, Inc.Method for making a laminar ventricular partitioning deviceUS9332993Mar 14, 2013May 10, 2016Cardiokinetix, Inc.Devices and methods for delivering an endocardial deviceUS9364327Mar 20, 2015Jun 14, 2016Cardiokinetix, Inc.Ventricular volume reductionUS9403329Sep 9, 2011Aug 2, 2016W. L. Gore & Associates, Inc.Method of increasing film tear strengthUS20020133054 *May 24, 2001Sep 19, 2002Gregory MurphySizing apparatus and method for use during ventricular restorationUS20020133227 *May 24, 2001Sep 19, 2002Gregory MurphyVentricular restoration patch apparatus and method of useUS20020169359 *May 2, 2002Nov 14, 2002Myocor, Inc.Methods and devices for improving cardiac function in heartsUS20030045771 *Aug 15, 2002Mar 6, 2003Schweich Cyril J.Heart wall tension reduction devices and methodsUS20030050529 *Oct 24, 2002Mar 13, 2003Myocor, Inc.Splint assembly for improving cardiac function in hearts, and method for implanting the splint assemblyUS20030050659 *Jul 31, 2002Mar 13, 2003Chase Medical, LpVentricular restoration shaping apparatusUS20030050682 *Aug 1, 2002Mar 13, 2003Sharkey Hugh R.Device for improving cardiac functionUS20030050685 *Aug 1, 2002Mar 13, 2003Nikolic Serjan D.Method for improving cardiac functionUS20030105384 *Nov 22, 2002Jun 5, 2003Sharkey Hugh R.Method of improving cardiac function using a porous membraneUS20030109770 *Nov 22, 2002Jun 12, 2003Sharkey Hugh R.Device with a porous membrane for improving cardiac functionUS20030181928 *Apr 10, 2003Sep 25, 2003Myocor, Inc.Endovascular splinting devices and methodsUS20030191538 *Apr 8, 2003Oct 9, 2003Buckberg Gerald D.Method of using ventricular restoration patchUS20030198919 *Apr 17, 2002Oct 23, 2003Henry HubnerProcess and apparatus for treating an exhaust stream from a dental operatoryUS20030233022 *Jun 9, 2003Dec 18, 2003Vidlund Robert M.Devices and methods for heart valve treatmentUS20040148019 *Nov 10, 2003Jul 29, 2004Vidlund Robert M.Devices and methods for heart valve treatmentUS20040148020 *Nov 10, 2003Jul 29, 2004Vidlund Robert M.Devices and methods for heart valve treatmentUS20050015109 *Jul 16, 2003Jan 20, 2005Samuel LichtensteinMethods and devices for altering blood flow through the left ventricleUS20050065396 *Jul 27, 2004Mar 24, 2005Myocor, Inc.External stress reduction device and methodUS20050075723 *May 7, 2004Apr 7, 2005Myocor, Inc.Methods and devices for improving mitral valve functionUS20050148815 *Jan 28, 2005Jul 7, 2005Myocor, Inc.Transventricular implant tools and devicesUS20050154252 *Jan 9, 2004Jul 14, 2005Cardiokinetix, Inc.Ventricular partitioning deviceUS20050197716 *Mar 3, 2004Sep 8, 2005Cardiokinetix, Inc.Inflatable ventricular partitioning deviceUS20050278024 *Apr 25, 2005Dec 15, 2005Gregory MurphyKit and method for use during ventricular restorationUS20060009799 *Jul 19, 2005Jan 12, 2006Kleshinski Stephen JEmbolic filtering method and apparatusUS20060014998 *Jun 10, 2005Jan 19, 2006Sharkey Hugh RMultiple partitioning devices for heart treatmentUS20060015143 *Jun 13, 2005Jan 19, 2006Alfredo AlvaradoLaparoscopic inguinal hernia prosthesisUS20060030881 *Aug 5, 2004Feb 9, 2006Cardiokinetix, Inc.Ventricular partitioning deviceUS20060036317 *Jul 7, 2005Feb 16, 2006Myocor, Inc.Decives and methods for heart valve treatmentUS20060041306 *Jul 1, 2005Feb 23, 2006Myocor, Inc.Devices and methods for heart valve treatmentUS20060052868 *Jul 1, 2005Mar 9, 2006Myocor, Inc.Valve to myocardium tension members device and methodUS20060149123 *Mar 7, 2006Jul 6, 2006Myocor, Inc.Splint assembly for improving cardiac function in hearts, and method for implanting the splint assemblyUS20060161040 *Dec 23, 2005Jul 20, 2006Myocor, Inc.Methods and devices for improving cardiac function in heartsUS20060195012 *Apr 14, 2006Aug 31, 2006Myocor, Inc.Valve to myocardium tension members device and methodUS20060229491 *Aug 9, 2005Oct 12, 2006Cardiokinetix, Inc.Method for treating myocardial ruptureUS20060241340 *Apr 14, 2006Oct 26, 2006Myocor, Inc.Methods and devices for improving mitral valve functionUS20060247491 *Apr 27, 2005Nov 2, 2006Vidlund Robert MDevices and methods for heart valve treatmentUS20060264980 *May 12, 2003Nov 23, 2006Alexander KhairkhahanSystem for improving cardiac functionUS20060281965 *Jun 10, 2005Dec 14, 2006Alexander KhairkhahanPeripheral seal for a ventricular partitioning deviceUS20070083076 *Jul 16, 2004Apr 12, 2007Samuel LichtensteinMethods and devices for altering blood flow through the left ventricleUS20070129598 *Dec 12, 2006Jun 7, 2007Raman JaishankerMethod and apparatus for external stabilization of the heartUS20070161846 *Dec 14, 2006Jul 12, 2007Serjan NikolicCardiac device and methods of use thereofUS20070198058 *May 19, 2006Aug 23, 2007Daniel GelbartMethod and device for closing holes in tissueUS20070213578 *May 7, 2007Sep 13, 2007Alexander KhairkhahanSystem for improving cardiac functionUS20070213815 *May 7, 2007Sep 13, 2007Alexander KhairkhahanSystem for improving cardiac functionUS20080004697 *Jun 28, 2006Jan 3, 2008Samuel Victor LichtensteinMethod for anchoring a mitral valveUS20080045778 *Aug 2, 2006Feb 21, 2008Samuel Victor LichtensteinSystem for improving diastolic dysfunctionUS20080161825 *Nov 20, 2007Jul 3, 2008Stout Medical Group, L.P.Anatomical measurement toolUS20080215074 *May 16, 2008Sep 4, 2008Raman JaishankarMethod and apparatus for external stabilization of the heartUS20080228205 *May 21, 2008Sep 18, 2008Cardiokinetix, Inc.Ventricular partitioning deviceUS20080319254 *May 29, 2008Dec 25, 2008Cardiokinetix, Inc.Therapeutic methods and devices following myocardial infarctionUS20080319256 *Jun 5, 2008Dec 25, 2008Myocor, Inc.Transventricular implant tools and devicesUS20090054723 *Aug 25, 2008Feb 26, 2009Alexander KhairkhahanRetrievable devices for improving cardiac functionUS20090062601 *Nov 10, 2008Mar 5, 2009Alexander KhairkhahanSystem for improving cardiac functionUS20090076597 *Sep 19, 2007Mar 19, 2009Jonathan Micheal DahlgrenSystem for mechanical adjustment of medical implantsUS20090149937 *Dec 5, 2008Jun 11, 2009Aesculap Ag, A Corporation Of GermanySheathing for restoring the function of valves of varicose veins and use of the sheathing in surgeryUS20090187063 *Jul 23, 2009Alexander KhairkhahanInflatable ventricular partitioning deviceUS20090254195 *Apr 10, 2009Oct 8, 2009Alexander KhairkhahanSystem for improving cardiac function by sealing a partitioning membrane within a ventricleUS20090270980 *Jul 7, 2009Oct 29, 2009Edwards Lifesciences LlcMethods and Devices for Improving Mitral Valve FunctionUS20090275976 *Nov 5, 2009Stout Medical Group, L.P.Embolic filtering method and apparatusUS20090287040 *Nov 19, 2009Alexander KhairkhahanPeripheral seal for a ventricular partitioning deviceUS20090287304 *May 13, 2008Nov 19, 2009Kardium Inc.Medical Device for Constricting Tissue or a Bodily Orifice, for example a mitral valveUS20100048987 *Aug 25, 2008Feb 25, 2010Alexander KhairkhahanRetrievable cardiac devicesUS20100081869 *Sep 28, 2009Apr 1, 2010Buckberg Gerald DVentricular Restoration PatchUS20100121132 *Jan 21, 2010May 13, 2010Serjan NikolicCardiac device and methods of use thereofUS20100185276 *Jul 22, 2010Edwards Lifesciences LlcDevices and Methods for Heart Valve TreatmentUS20100222789 *May 11, 2010Sep 2, 2010Kardium Inc.Method and device for closing holes in tissueUS20100262168 *Oct 14, 2010Alexander KhairkhahanSealing and filling ventricular partitioning devices to improve cardiac functionUS20100274076 *Oct 28, 2010Edwards Lifesciences LlcHeart Wall Tension Reduction Apparatus and MethodUS20100274227 *Feb 10, 2010Oct 28, 2010Alexander KhairkhahanDelivery catheter handle coverUS20110022166 *Jan 27, 2011Kardium Inc.Medical device for constricting tissue or a bodily orifice, for example a mitral valveUS20110087066 *Sep 29, 2010Apr 14, 2011Boutillette Michael PDevices and methods for delivering an endocardial deviceUS20110087203 *Apr 14, 2011Kardium Inc.System for improving diastolic dysfunctionUS20120010708 *Jan 12, 2012AFcell MedicalAmnion and chorion replacement cover and uses thereof in surgical repair of musclesEP3058878A1Sep 9, 2011Aug 24, 2016W. L. Gore & Associates, Inc.Method of increasing film tear strengthWO2012033977A1Sep 9, 2011Mar 15, 2012Gore Enterprise Holdings, Inc.Method of increasing film tear strength* Cited by examinerClassifications U.S. Classification600/37, 623/23.72, 623/3.1International ClassificationA61F2/00, A61F2/24Cooperative ClassificationA61F2/2481, A61F2/2487, A61F2/2478, A61F2/2445European ClassificationA61F2/24W, A61F2/24W2Legal EventsDateCodeEventDescriptionMar 6, 2002ASAssignmentOwner name: CORRESTORE, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUCKBERG, GERALD D.;ATHANASULEAS, CONSTANTINE L.;REEL/FRAME:012657/0205;SIGNING DATES FROM 20020208 TO 20020211Aug 8, 2006FPAYFee paymentYear of fee payment: 4Sep 8, 2010FPAYFee paymentYear of fee payment: 8Nov 14, 2014REMIMaintenance fee reminder mailedApr 8, 2015LAPSLapse for failure to pay maintenance feesMay 26, 2015FPExpired due to failure to pay maintenance feeEffective date: 20150408RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services